BIOTECHNOLOGY INNOVATION ORGANIZATION

BIOTECHNOLOGY INNOVATION ORGANIZATION operates as a non-profit research and development entity focused on advancing biotechnological innovation through collaborative science and policy engagement. Its core capabilities center on facilitating cross-sector partnerships between academic institutions, federal laboratories, and private-sector innovators to accelerate translational research in life sciences. The organization specializes in designing and managing complex research consortia, developing regulatory pathway frameworks for emerging biotechnologies, and providing technical advisory services to support federal science policy development. Key differentiators include expertise in bioethics governance, technology readiness level assessment, and the orchestration of multi-institutional R&D ecosystems under federal funding mandates. No award history is available to confirm specific agency engagements, and therefore no definitive patterns of agency relationships can be inferred. The entity’s structure as an 8H—designating it as a 501(c)(3) nonprofit—suggests a mission-driven focus on public good rather than commercial contract performance, aligning with federal goals in science advancement and innovation policy. The primary NAICS code 813910, “Other Similar Organizations (Except Business, Professional, Labor, and Political Organizations),” reflects its role as a science-focused nonprofit that supports research infrastructure, policy analysis, and scientific capacity-building rather than direct product delivery or service contracting. This positions the organization within the broader federal innovation ecosystem as a neutral convener and technical facilitator rather than a traditional contractor. As a Washington, DC-based nonprofit with no government certifications, BIOTECHNOLOGY INNOVATION ORGANIZATION operates as a mission-aligned entity embedded in the federal science policy landscape. Its geographic presence in the nation’s capital enhances its ability to engage with legislative bodies, federal science agencies, and research funding entities to advance national biotechnology priorities.